Notification about latest news from us.
Donald Trump announces impending major tariffs on pharmaceutical imports, raising concerns about soaring drug prices and potential shortages.
The FDA has approved Journavx, a new non-opioid pain medication, aiming to combat opioid addiction and overdose risks in patients.
Trump's tariffs pose significant challenges for the pharmaceutical industry, impacting costs and accessibility.
Major drug companies plan to raise prices on over 250 medications in the U.S., effective January 1, 2025, with median increases around 4.5%.
By clicking send you'll receive occasional emails from newsletters about this topic.